C Max Schmidt Selected Research

Pancreatic Cyst

11/2022	Serial EUS-Guided FNA for the Surveillance of Pancreatic Cysts: A Study of Long-Term Performance of Tumor Markers.
2/2021	Novel expression of vascular endothelial growth factor isoforms in the pancreas and pancreatic cystic lesions.
1/2021	Biomarker Risk Score Algorithm and Preoperative Stratification of Patients with Pancreatic Cystic Lesions.
1/2020	Performance of candidate urinary biomarkers for pancreatic cancer - Correlation with pancreatic cyst malignant progression?
1/2019	Pancreatic Fluid Interleukin-1β Complements Prostaglandin E2 and Serum Carbohydrate Antigen 19-9 in Prediction of Intraductal Papillary Mucinous Neoplasm Dysplasia.
1/2018	Pancreatic cyst fluid glucose: rapid, inexpensive, and accurate diagnosis of mucinous pancreatic cysts.
10/2017	Prostaglandin E2: A Pancreatic Fluid Biomarker of Intraductal Papillary Mucinous Neoplasm Dysplasia.
8/2017	Global Protease Activity Profiling Provides Differential Diagnosis of Pancreatic Cysts.
5/2017	Pancreatic Cyst Fluid Vascular Endothelial Growth Factor A and Carcinoembryonic Antigen: A Highly Accurate Test for the Diagnosis of Serous Cystic Neoplasm.
10/2014	The natural history of main duct-involved, mixed-type intraductal papillary mucinous neoplasm: parameters predictive of progression.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

C Max Schmidt Research Topics

Disease

43	Neoplasms (Cancer) 10/2022 - 04/2002
32	Pancreatic Neoplasms (Pancreatic Cancer) 01/2021 - 04/2002
18	Neoplasms, Cystic, Mucinous, and Serous 02/2021 - 05/2010
16	Adenocarcinoma 01/2020 - 07/2004
15	Pancreatic Cyst 11/2022 - 02/2008
14	Cysts 11/2022 - 02/2004
10	Pancreatic Fistula (Pancreatic Fistulas) 01/2022 - 12/2007
9	Hepatocellular Carcinoma (Hepatoma) 04/2010 - 12/2003
8	Pancreatitis 01/2022 - 10/2014
6	Infections 01/2022 - 05/2013
6	Carcinogenesis 01/2021 - 04/2005
4	Pain (Aches) 01/2022 - 04/2002
4	Chronic Pancreatitis 01/2021 - 10/2011
4	Necrosis 01/2021 - 12/2009
4	Neoplasm Metastasis (Metastasis) 04/2013 - 04/2008
3	Margins of Excision 10/2022 - 05/2009
3	Weight Loss (Weight Reduction) 01/2022 - 10/2014
2	Urinary Tract Infections (Urinary Tract Infection) 01/2022 - 10/2018
2	Jaundice (Icterus) 01/2022 - 06/2003
2	Pulmonary Embolism 01/2021 - 01/2019
2	Pathologic Constriction (Stenosis) 01/2021 - 02/2016
2	Acute Necrotizing Pancreatitis 01/2021 - 12/2009
2	Surgical Wound Infection 10/2019 - 10/2018
2	Primitive Neuroectodermal Tumors (PNET) 03/2019 - 05/2009
2	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2019 - 01/2019
2	Wound Infection (Wound Infections) 01/2019 - 01/2009
2	Inflammation (Inflammations) 10/2014 - 04/2009
2	Abdominal Abscess 04/2014 - 01/2009
2	Hepatitis 08/2009 - 06/2009
1	Sepsis (Septicemia) 10/2022
1	Thrombosis (Thrombus) 10/2022
1	Hyperamylasemia 01/2022
1	Urinary Retention 01/2022
1	Biliary Fistula 01/2021

Drug/Important Bio-Agent (IBA)

13	Biomarkers (Surrogate Marker)IBA 02/2021 - 01/2008
10	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 04/2010 - 11/2003
9	Proteins (Proteins, Gene)FDA Link 02/2021 - 06/2007
8	DNA (Deoxyribonucleic Acid)IBA 11/2022 - 11/2003
6	NF-kappa B (NF-kB)IBA 04/2013 - 04/2005
6	Sulindac (Copal)FDA LinkGeneric 11/2009 - 03/2003
5	Carcinoembryonic AntigenIBA 01/2021 - 04/2007
5	Gemcitabine FDA Link 10/2015 - 02/2008
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2021 - 04/2014
4	Amylases FDA Link 01/2021 - 12/2011
4	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 06/2003
4	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 10/2017 - 03/2003
4	parthenolideIBA 12/2013 - 04/2005
4	Transcription Factors (Transcription Factor)IBA 04/2013 - 04/2005
4	CarcinogensIBA 11/2009 - 06/2006
3	Tumor Biomarkers (Tumor Markers)IBA 11/2022 - 06/2003
3	EnzymesIBA 01/2022 - 10/2014
3	MucinsIBA 01/2021 - 02/2004
3	Secretin FDA Link 08/2020 - 03/2012
3	Anti-Bacterial Agents (Antibiotics)IBA 01/2020 - 01/2019
3	Biological ProductsIBA 03/2019 - 06/2008
3	Dinoprostone (PGE2)FDA Link 01/2019 - 06/2006
3	Indicators and Reagents (Reagents)IBA 10/2018 - 02/2008
3	U 0126 (UO 126)IBA 06/2009 - 11/2003
3	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 10/2008 - 12/2003
3	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 11/2007 - 12/2003
2	VaccinesIBA 01/2022 - 01/2020
2	Lipase (Acid Lipase)FDA Link 01/2021 - 10/2014
2	CarbohydratesIBA 01/2019 - 04/2007
2	ProinsulinIBA 01/2019 - 01/2019
2	CA-19-9 Antigen (CA 19-9 Antigen)IBA 01/2019 - 04/2007
2	Glycoproteins (Glycoprotein)IBA 01/2019 - 07/2012
2	Circulating Tumor DNAIBA 01/2017 - 02/2014
2	Alkaline PhosphataseIBA 10/2014 - 06/2003
2	Polysaccharides (Glycans)IBA 07/2012 - 05/2010
2	LC-1 compoundIBA 07/2012 - 10/2008
2	mirdametinibIBA 04/2010 - 01/2008
2	Transforming Growth Factor alpha (TGF-alpha)IBA 06/2009 - 01/2008
2	2- (2- chloro- 4- iodophenylamino)- N- cyclopropylmethoxy- 3,4- difluoro- 5- bromobenzamideIBA 06/2009 - 01/2006
2	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 06/2009 - 12/2008
2	Mitogen-Activated Protein KinasesIBA 06/2009 - 03/2004
2	Celecoxib (Celebrex)FDA Link 10/2008 - 11/2007
2	ProstaglandinsIBA 02/2008 - 11/2007
2	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 06/2007 - 06/2006
1	Analgesics (Analgesic Drugs)IBA 01/2022
1	N 30IBA 01/2022
1	human VEGFA proteinIBA 02/2021
1	Protein Isoforms (Isoforms)IBA 02/2021
1	Codon (Codons)IBA 01/2021

Therapy/Procedure

15	Therapeutics 04/2020 - 03/2003
14	Pancreatectomy 10/2022 - 10/2007
14	Pancreaticoduodenectomy 01/2021 - 10/2007
11	Drug Therapy (Chemotherapy) 01/2022 - 06/2006
10	Length of Stay 01/2022 - 12/2007
4	Debridement 01/2022 - 12/2009
3	Operative Time 01/2021 - 07/2010
3	Splenectomy 01/2020 - 04/2010
3	Chemoprevention 04/2013 - 01/2008
3	Radiotherapy 01/2011 - 04/2008
2	Neoadjuvant Therapy 10/2022 - 10/2011
2	Catheters 01/2022 - 10/2018
2	Patient Readmission 01/2021 - 05/2013
2	Gastrostomy 12/2020 - 01/2019
2	Pancreaticojejunostomy 02/2016 - 05/2009
1	Urinary Catheters 01/2022
1	Contraindications 01/2021